For the first three months of the year, U.S. biotech venture funding rounds reached $391 million, a 34% increase to figures for the same period last year, according to BioWorld data. The biggest increases came in support of early-stage innovations: Series A and seed deals brought in 63% more funding in the first quarter. The trend suggests the biotech industry could be a healthier environment for investing in 2012.

Related Summaries